11 мая 2022 г. · In a phase 1b study, lenacapavir showed substantial antiviral activity. In the ongoing phase 3 CAPELLA trial, we assessed the efficacy and ...

12 мая 2022 г. · Lenacapavir is a first-in-class capsid inhibitor that showed substantial antiviral activity in a phase 1b study.

6 мар. 2024 г. · In CAPELLA, LEN in combination with an optimized background regimen (OBR) led to high virologic suppression: 78% (n=56/72; week [W] 52). We ...

11 июл. 2023 г. · Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial

We designed the ongoing phase 2/3 CAPELLA study to evaluate the efficacy and safety of lenacapavir in participants with multidrug-resistant HIV-1. As ...

24 июл. 2023 г. · These data demonstrate lenacapavir plus OBR has the potential to be an effective HIV regimen without compromising health-related quality of life.

The ongoing CAPELLA trial (NCT04150068) established the efficacy of lenacapavir plus an investigator-selected OBR in people with multidrug-resistant virus: 82% ...

SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

11 июл. 2023 г. · We aimed to evaluate the efficacy and safety of lenacapavir with an optimised background regimen in adults living with multidrug-resistant HIV-1 up to 52 weeks.

23 июл. 2024 г. · The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen.